Recent Updates
Recently added Catalysts
PEPG Positive Sentiment Score: 75/100

PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

Key Takeaway: PepGen Inc., a clinical-stage biotechnology company focusing on oligonucleotide therapies, announced its participation in the Bank of America Securities 2023 Healthcare Conference. The event will feature a presentation by the company's President and CEO, James McArthur, on May 11th in Las Vegas, Nevada. PepGen's technology, which includes its Enhanced Delivery Oligonucleotide platform, aims to improve treatment for severe neuromuscular and neurological diseases. A live webcast of the event will be available, along with a one-year archived replay.

Market Sentiment Analysis

POSITIVE FACTORS

  • PepGen is advancing the next generation of oligonucleotide therapies.
  • The CEO is presenting at a prominent healthcare conference.
  • The company has a pipeline of therapeutic candidates targeting serious diseases.

Full Press Release Details

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the Bank of America Securities 2023 Healthcare Conference on Thursday, May 11th at 12:20pm EDT in Las Vegas, Nevada.
The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen’s website. A replay of the event will be archived for one year.
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

Frequently Asked Questions

What is PepGen Inc. focused on?

PepGen Inc. is advancing the next generation of oligonucleotide therapies for severe neuromuscular and neurological diseases.

Who will present at the Bank of America Conference?

James McArthur, Ph.D., President and CEO of PepGen, will present at the conference.

When is PepGen's presentation at the conference?

The presentation is scheduled for May 11th at 12:20pm EDT.

Where can I watch the PepGen conference presentation?

The presentation will be webcast live on PepGen's Investor Relations website.

What is EDO in PepGen's research?

EDO stands for Enhanced Delivery Oligonucleotide, aimed at improving therapeutic uptake.

Last updated: May 4, 2023